ATOS 8-K: SEC filing
Atossa Therapeutics
Filed with the SEC on · accession 0001193125-26-454486
ATOS filed a 8-K (current report) with the SEC on Nov 10, 2026. Atossa Therapeutics issued a press release announcing its financial results for the third quarter ended September 30, 2026, along with a company update.
Summary of the filing
Atossa Therapeutics issued a press release announcing its financial results for the third quarter ended September 30, 2026, along with a company update. The press release was furnished as Exhibit 99.1 to the Form 8-K.
Key details
✦ Ask GOAX AI about this filing — what it means for ATOS, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for ATOS?
Click hereFrequently asked questions
What did ATOS file with the SEC on Nov 10, 2026?
ATOS filed a 8-K (SEC filing). Atossa Therapeutics issued a press release announcing its financial results for the third quarter ended September 30, 2026, along with a company update. The press release was furnished as Exhibit 99.1 to the Form 8-K.
How do I read a 8-K?
A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.
Why are SEC filings important?
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.
Other ATOS SEC filings
Get alerts when ATOS files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days